Synthetic statins: More data on newer lipid-lowering agents

Current Medical Research and Opinion

Volumn 17, Issue 1, 2001, Pages 74-77

  Wierzbicki, A S ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

C reactive protein; HDL cholesterol; HMG CoA reductase inhibitors (statins); LDL cholesterol; Randomised controlled trials

Indexed keywords

ANTILIPEMIC AGENT; C REACTIVE PROTEIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STATIN;

ATHEROSCLEROSIS; DISEASE ASSOCIATION; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; HYPERLIPIDEMIA; PROPHYLAXIS; REVIEW;

ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; FATTY ACIDS, MONOUNSATURATED; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LIPIDS; PYRIDINES; PYRROLES; SIMVASTATIN;

EID: 0034951457     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990152005388     Document Type: Review

References (34)

1. Natural statins and stroke
2. Increased thrombotic vascular events after change of statin
3. Thrombotic vascular events after change of statin
4. HDL cholesterol and the treatment of coronary heart disease
5. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia
6. Comparison of statins in hypertriglyceridemia
7. High-density lipoprotein cholesterol and triglyceride response with simvastatin vs. atorvastatin in familial hypercholesterolemia
8. Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia
9. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels
10. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-1 levels
11. Development of tachyphylaxis among patients taking HMG-CoA reductase inhibitors
12. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomised, double-blind trial
13. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
14. Randomised, double-blind, parallel-group trial of atorvastatin and fluvastatin on plasma lipid levels in patients with untreated hyperlipidaemia
15. CAVEAT: A randomised double-blind, parallel group evaluation of cerivastatin 0.4 mg and 0.8 mg compared to atorvastatin 10 mg and 20 mg once daily in patients with combined (type IIb) dyslipidaemia
16. C-reactive protein-mediated lipoprotein uptake by macrophages
17. Long-term effects of pravastatin on plasma concentration of C-reactive protein
18. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia
19. Statins and C-reactive protein
20. Effect of atorvastatin on plasma fibrinogen
21. The effect of atorvastatin on serum lipids, lipoprotein (a) and plasma fibrinogen levels in primary dyslipidaemia - A pilot study involving serial sampling
22. Effects of Bay W 6228 on coagulation tests in patients with hyperlipidemia
23. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin alone and in combination treatment
24. Pravastatin and the development of diabetes mellitus. Evidence for a protective treatment effect in the West of Scotland coronary prevention project
25. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients
26. Hypotensive effect of an inhibitor of cholesterol synthesis (fluvastatin). A pilot study
27. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia
28. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease
29. Atorvastatin versus revascularization treatment (AVERT): Fact or fancy?
30. The AVERT trial
31. A randomised placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: Final results of the FLuvastatin Angiographic Restenosis (FLARE) trial
32. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])
33. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment
34. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes